New hormone combo aims to save fertility in early uterine cancer
NCT ID NCT05247268
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether a combination of a gonadotropin-releasing hormone agonist (triptorelin) and letrozole can achieve better complete response rates than standard hormone therapy (megestrol acetate or medroxyprogesterone acetate) in women with early-stage endometrial cancer who wish to preserve fertility. About 104 participants will be enrolled and followed for up to 28 weeks to see how well the cancer responds and to monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gonadotropin-releasing hormone agonist (triptorelin) plus letrozole
- What this could lead to
- If successful, this could offer a more effective fertility-sparing option for women with early endometrial cancer, helping them avoid hysterectomy and preserve the chance to have children.
- What could go wrong
- This is a small, early-phase trial, so results may not be conclusive. The combination therapy may cause side effects like hot flashes or joint pain, and it's not yet known if it works better than standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Obstetrics and Gynecology Hospital, Fudan University
RECRUITINGShanghai, 200011, China